Neurotherapeutics devices company MindMaze Healthcare has announced its commercial product portfolio and clinical pipeline which includes two new pieces of software.
MindMaze recently revealed its newest set of products which are focused on neurorehabilitation and neuro-restoration.
The firm’s Rehab DTx platform provides therapists with serious digital games that show AI-generated performance data to show how a patient is progressing.
The telerehabilitation service has helped a number of patients while freeing up time for clinicians while allowing them to roll out the services to a high number of patients.
Crucially during the pandemic it has opened up opportunities for in-hospital and home-base care.
Following this is the Neuro DTx, which allows clinicians to prescribe specialist software to patients that promotes repair and reorganisation in the nervous system after disease or injury.
These products are expected to provide MindMaze with ‘exceptional growth’ over the next few years as it looks to expand its presence through strategic partnerships.
Tej Tadi, founder and CEO at the company said: “At MindMaze, we are leading the delivery of digital neurotherapeutics with our groundbreaking solutions for some of the most challenging neurological conditions.”
“We are differentiated in the burgeoning digital therapeutics industry. MindMaze has a global commercial footprint that is generating considerable revenue today and will drive explosive revenue growth in the next years.”
On top of its rehabilitation software, the Swiss-based company also offers AI cloud-based assessment games that can be used to determine a patient’s potential for recovery.
Video games have become a vital asset when it comes to getting patients engaged in their health, as Health Tech World recently covered when looking at BfB Labs’ app that was being used to diagnose anxiety disorders in children.
They also have diagnostic potential, with researchers from the University of Strathclyde creating two new prototype devices that could be used to recognise children suffering from ‘lazy eye.’
A number of leading institutions such as Johns Hopkins University Hospital and Mt. Sinai Health is using the software, which is also available in 20 different countries worldwide.
John Krakauer, Professor of Neurology at Johns Hopkins University and chief medical advisor for the firm, said: “MindMaze products are changing the way patients with neurological conditions are treated, empowering patients and significantly enhancing their clinical outcomes.”
Currently the firm is developing products for eight major neurological conditions, including: stroke, TBI, mild cognitive impairment (MCI), Alzheimer’s, Parkinson’s, autism spectrum disorders, MS and frailty.
Over the next few years MindMaze will work with top academic institutions to develop a body of clinical evidence for its existing products, while also finalising new therapeutic solutions for chronic stroke, PD, and MCI.